EVENTS · REGN
PEERS
EARNINGS
Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, manufactures, and commercializes medicines for people with serious diseases. Its portfolio spans treatments in eye care, immunology, oncology, cardiovascular and metabolic disease, infectious disease, hematology, and rare disorders. The company is known for combining laboratory research, clinical development, and in-house manufacturing to advance biologic therapies and antibody-based medicines. Regeneron also works on product candidates across multiple therapeutic areas, supporting a broad drug pipeline alongside its marketed medicines. Regeneron Pharmaceuticals, Inc. plays an important role in the healthcare market through its focus on specialty therapies designed for complex and often chronic medical conditions.
No company news, with biotech stocks higher as a group and the broader market also up while Regeneron fell on its own
| Series | 1W | 1M |
|---|---|---|
| REGN | +14.4% | +26.0% |
| Peers | +1.4% | +4.9% |
| Sector · Health Care | +5.6% | +13.5% |
| SPY | −0.7% | −1.6% |
| Percentile rank vs S&P 500 | 95 | 97 |
| QUARTER | EPS EST | EPS ACTUAL | EPS SURPRISE | REACTION |
|---|---|---|---|---|
| Q3 FY2026 | 13.76 | 20.07 | +45.86% | +17.40% |
| Q2 FY2026 | 10.47 | 14.29 | +36.51% | +9.66% |
| Q1 FY2026 | 9.12 | 9.47 | +3.88% | −3.38% |
| Q4 FY2025 | 10.83 | 11.44 | +5.65% | +0.74% |
| Q3 FY2025 | 9.78 | 11.83 | +20.96% | +11.55% |
| Series | 1W | 1M |
|---|---|---|
| REGN | +14.4% | +26.0% |
| Peers | +1.4% | +4.9% |
| Sector · Health Care | +5.6% | +13.5% |
| SPY | −0.7% | −1.6% |
| Percentile rank vs S&P 500 | 95 | 97 |
